JournalsHub
.online
Find My Journal
JF

Joseph W. Fay

Northeast Ohio Medical University US

159
Publications
10,484
Citations
52
H-Index
88
i10-Index
2.0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma OA

D. Pan, J. Kaufman, M. Htut, M. Agrawal, A. Mazumder - Cancer Medicine, 2021
Cited by 10 Semantic Scholar

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

T. Facon, S. Lonial, B. Weiss, A. Suvannasankha, J. Fay - Unknown Venue, 2017
Cited by 18 Semantic Scholar

A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM).

H. Cho, C. Cole, T. Martin, J. Zonder, J. Fay - Unknown Venue, 2017
Cited by 4 Semantic Scholar

Human Dendritic Cell Subsets In Vivo Colony-Stimulating Factor Mobilize Distinct Flt3-Ligand and Granulocyte

K. Palucka, C. Maliszewski, J. Davoust, J. Fay, E. Kraus - Unknown Venue, 2017
Cited by 0 Semantic Scholar

Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy

A. Chari, A. Suvannasankha, J. Fay, B. Arnulf, J. Kaufman - Unknown Venue, 2017
Cited by 1 Semantic Scholar

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. OA

A. Chari, A. Suvannasankha, J. Fay, B. Arnulf, J. Kaufman - Blood, 2017
Cited by 428 Semantic Scholar

Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. OA

C. Flowers, L. Costa, M. Pasquini, J. Le-Rademacher, M. Lill - Biology of Blood and Marrow Transplantation, 2016
Cited by 21 Semantic Scholar

Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study

J. Keats, G. Speyer, Austin W. Christofferson, Christophe Legendre, J. Aldrich - Unknown Venue, 2016
Cited by 13 Semantic Scholar

A phase 1 dose‐escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma OA

A. Chari, M. Htut, J. Zonder, J. Fay, A. Jakubowiak - Cancer, 2016
Cited by 35 Semantic Scholar

Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma

A. Chari, S. Lonial, A. Suvannasankha, J. Fay, B. Arnulf - Unknown Venue, 2015
Cited by 70 Semantic Scholar

Research Topics

Immunotherapy and Immune Responses (43) Hematopoietic Stem Cell Transplantation (39) Multiple Myeloma Research and Treatments (24) vaccines and immunoinformatics approaches (22) T-cell and B-cell Immunology (21)

Affiliations

Translational Genomics Research Institute
US 2015 - 2015
Cleveland Clinic
US 1987 - 1981
Howard Hughes Medical Institute
US 1981 - 1981
University of British Columbia
CA 1986 - 1986
University of Louisville
US 1999 - 1999

External Profiles

OpenAlex Profile Semantic Scholar Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now